Valeant Stock Drops Making Allergan Deal Tougher

HFA Padded
Mark Melin
Published on
Updated on
valeant pharmaceuticals

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), a “roll-up” company embroiled in a bitter battle to take over Botox-maker Allergan, Inc. (NYSE:AGN), reported earnings Thursday that showed climbing and strong growth. Valeant’s stock price tumbles after earnings While the company was making a case to purchase Botox maker Allergan, Inc. (NYSE:AGN), which relies on its stock price as a currency in the acquisition, its saw this stock price tumble after its earnings announcement. This is a problem for Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), which Allergan, Inc. (NYSE:AGN) has accused of relying on buyout deals to expand its business, rather than…

This content is exclusively for paying members of Hedge Fund Alpha

Log In

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe now and get 7 days free!

HFA Padded

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.